Current Management of Chronic Myeloid Leukemia Myeloid Blast Phase.
Clin Med Insights Oncol
; 16: 11795549221139357, 2022.
Article
em En
| MEDLINE
| ID: mdl-36507316
ABSTRACT
Despite the major advancements in the management of chronic phase (CP) chronic myeloid leukemia (CML), blast crisis (BC) remains a major therapeutic challenge. BC can be myeloid, lymphoid, or mixed lineage with myeloid BC being the most common type. BC in CML is mediated by aberrant tyrosine kinase activity of the BCRABL fusion protein. The introduction of BCRABL tyrosine kinase inhibitor (TKI) has been a gamechanger in the treatment of CML and there has been a significant reduction in the incidence of BC. The main treatment goal in BC is to achieve a second CP and consolidate that with an allogeneic stem cell transplantation (SCT) in eligible patients. The outcomes in BC remain dismal even in the current era. In this review, we provide an overview of the biology and current therapeutic approach in myeloid BC.
Texto completo:
1
Base de dados:
MEDLINE
Idioma:
En
Revista:
Clin Med Insights Oncol
Ano de publicação:
2022
Tipo de documento:
Article
País de afiliação:
Estados Unidos